Catalent & Sanofi to Collaborate
News Jan 22, 2015
Catalent Pharma Solutions has entered into a collaboration with Sanofi -Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates (ADCs).
Under the agreement, Catalent will develop site-specifically modified antibody conjugates using Sanofi’s proprietary antibodies. Catalent’s precision protein-chemical engineering approach will enable Sanofi to evaluate site selective payload conjugation in order to enhance ADC pharmacokinetics, efficacy and safety.
The collaborative work will involve teams at Sanofi, and Catalent’s facility, in Emeryville, CA, which was formerly headquarters to Redwood Bioscience Inc. Catalent announced in October 2014 that it had purchased the remaining stake in Redwood, following the successful achievement of in vivo and in vitro proof of concept milestones, recent compelling in vivo toxicology data, and strong customer interest in the SMARTag technology.
“We are pleased to enter this agreement with Sanofi as we jointly work toward the goal of creating better drugs to meet patient needs,” commented Barry Littlejohns, Catalent’s President of Advanced Delivery Technologies. “Through in vivo toxicology studies, we have demonstrated that ADCs generated using Catalent’s SMARTag platform have a better toxicity profile than a conventional ADC, while efficacy studies also point to an improved therapeutic index. We look forward to partnering with Sanofi to support the development of their next generation of ADC products.”
The proprietary SMARTag site-specific protein modification and cytotoxin-linker technologies developed by Redwood enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability.
The technology employs natural post translational modifications found in human cells to create one or more aldehyde tags at designated sites on protein molecules. These chemical handles are then stably conjugated to cytotoxic payloads to prevent their systemic release.
The SMARTag platform provides precise payload positioning and defined stoichiometry of payload–protein ratios. The control afforded by the technology enables identification of superior drugs from libraries of differentially designed conjugates.
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018